Answers are grounded in this paper and cite their sources.
; however, there are no commercial molecular assays for HTLV-1 available globally. While some countries are strengthening their efforts to diagnose HTLV-1 and prevent transmission (i.e., Brazil introduced universal antenatal screening in 2024), the prevalence of HTLV-1 in many parts of the world is unknown. Unsurprisingly, there is great inequity in access to molecular HTLV testing services, which can importantly contribute both as part of a diagnostic confirmatory testing algorithm and be used to monitor disease. Due to the lack of commercially available molecular assays, laboratories rely on in-house developed protocols, resulting in substantial variability in methodologies and access to testing. An HTLV Testing Working Group was established by the International Retrovirology Association in 2023 with the objective to improve access to and the quality of molecular testing for HTLV-1 globally. Representatives from nine laboratories in Argentina, Australia, Brazil, Iran, Japan, Sweden, and the United Kingdom have collaboratively compared their in-house molecular protocols. The methods are presented and summarized with a discussion of the relative strengths and limitations of each platform and key considerations for laboratories establishing molecular HTLV testing capacity. This analysis provides a practical framework supporting equitable expansion of HTLV molecular diagnostics globally, aiming to help countries with varying access to funding to be able to select the assay best suited to their means while recognizing the relative risks and benefits.
No takes yet. Share an insight, caveat, or question.
Rowan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: